Prelude Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-99.5	-127.17	-121.83	-115.44	-111.69
Depreciation & Amortization	1.71	1.77	1.17	1.32	0.92
Stock-Based Compensation	11.91	21.35	25.62	25.14	20.93
Other Adjustments	1.16	-3.05	-1.54	4.31	2.69
Changes in Accounts Payable	-3.92	3.31	-2.27	-0.35	3.9
Changes in Accrued Expenses	-2.98	-0.81	2.52	6.83	2.46
Changes in Unearned Revenue	35.53	-	-	-	-
Changes in Other Operating Activities	-0.23	1.72	-10.73	-5.55	-2.74
Operating Cash Flow	-56.3	-102.89	-107.06	-83.73	-83.53
Capital Expenditures	-0.07	-0.76	-3.51	-3.02	-2.32
Purchases of Investments	-100.87	-52.69	-221.63	-119.22	-261.48
Proceeds from Sale of Investments	154.39	143.65	190.5	203.93	-
Investing Cash Flow	53.46	90.19	-34.65	81.69	-263.8
Issuance of Common Stock	25.04	0.44	136.41	0.82	165.2
Net Common Stock Issued (Repurchased)	25.04	0.44	136.41	0.82	165.2
Other Financing Activities	-0.23	-0.56	-0.02	-	-0.3
Financing Cash Flow	24.82	-0.12	136.4	0.82	164.9
Net Cash Flow	21.97	-12.82	-5.31	-1.22	-182.44
Free Cash Flow	-56.37	-103.65	-110.58	-86.75	-85.85
FCF Margin	-464.32%	-1480.74%	-	-	-
Free Cash Flow Per Share	-0.73	-1.37	-1.83	-1.83	-1.86
Levered Free Cash Flow	-69.45	-121.95	-134.66	-116.2	-109.48
Unlevered Free Cash Flow	-74.51	-134.49	-145.1	-124.3	-111.52

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q